Eli Lilly's arthritis drug fails to meet main goal of late-stage COVID-19 study
April 8 (Reuters) - Rheumatoid arthritis drug baricitinib developed by Eli Lilly and Co and Incyte Corp did not meet the main goal of a late-stage study in hospitalized COVID-19 patients, the drugmakers said on Thursday.
Baricitinib has been granted emergency use authorization by the U.S. Food and Drug Administration in combination with remdesivir for COVID-19 patients requiring supplemental oxygen. (Reporting by Mrinalika Roy in Bengaluru; Editing by Aditya Soni)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.